Although metabolic disorder has been widely accepted to become a critical risk factor of cardiovascular diseases, the mechanisms underlying the promotional effects of metabolic disorder on cardiovascular diseases are not fully understood. In addition to statins, in recent years, some other metabolic regulatory drugs, such as GLP-1 receptor agonists and SGLT2 inhibitors, have also displayed excellent protective effects on cardiovascular system in several large-scale clinical studies, thus becoming a new first-line drug for metabolic cardiovascular diseases. Therefore, the intervention of cardiovascular disease by improving metabolism is a promising therapeutic direction.
Recent studies have confirmed that metabolic organs not only regulate blood glucose and blood lipid levels, but also secrete a large number of metabolic regulatory factors, such as FGF21, ANGPTL, Fetuin-A secreted by the liver, adiponectin and leptin secreted by adipose tissue, myostatin and irisin secreted by muscle tissue, etc. These regulatory factors can regulate the structure and function of the heart and blood vessels, thus playing a vital role in the occurrence of cardiovascular diseases. Further studies on this topic are emergently important and advances in this field can significantly improve our understanding of cardiovascular diseases and would provide novel and alternative therapeutic strategies.
In this Research Topic, we aim to focus on recent advances and studies investigating molecular mechanisms linking metabolic secretory factors and cardiovascular diseases, as well as their diagnostic and therapeutic value of metabolic cardiometabolic diseases.
We welcome submissions of Original Research, Review and Mini-review articles on the following subtopics, but not limited to:
- Role of metabolic organ-secreted factors (hepatokines, adipokines, myokines, etc.) as biomarkers and targets for diagnosis of cardiovascular and metabolic diseases
- Receptors and corresponding signaling pathways responsible for the regulatory role of metabolic organ-secreted factors in cardiometabolic system
- Molecular mechanism of abnormal expression and secretion of metabolic organ-secreted factors in cardiovascular diseases
- Association between metabolic organ-secreted factors and pathological changes in cardiometabolic diseases, such as cardiac hypertrophy and vascular remodeling
- Role of metabolic organ-secreted factors in the treatment of cardiovascular diseases and molecular mechanism of the metabolic therapies on cardiovascular disease
- Crosstalk between local adipose tissue and cardiovascular cells
Although metabolic disorder has been widely accepted to become a critical risk factor of cardiovascular diseases, the mechanisms underlying the promotional effects of metabolic disorder on cardiovascular diseases are not fully understood. In addition to statins, in recent years, some other metabolic regulatory drugs, such as GLP-1 receptor agonists and SGLT2 inhibitors, have also displayed excellent protective effects on cardiovascular system in several large-scale clinical studies, thus becoming a new first-line drug for metabolic cardiovascular diseases. Therefore, the intervention of cardiovascular disease by improving metabolism is a promising therapeutic direction.
Recent studies have confirmed that metabolic organs not only regulate blood glucose and blood lipid levels, but also secrete a large number of metabolic regulatory factors, such as FGF21, ANGPTL, Fetuin-A secreted by the liver, adiponectin and leptin secreted by adipose tissue, myostatin and irisin secreted by muscle tissue, etc. These regulatory factors can regulate the structure and function of the heart and blood vessels, thus playing a vital role in the occurrence of cardiovascular diseases. Further studies on this topic are emergently important and advances in this field can significantly improve our understanding of cardiovascular diseases and would provide novel and alternative therapeutic strategies.
In this Research Topic, we aim to focus on recent advances and studies investigating molecular mechanisms linking metabolic secretory factors and cardiovascular diseases, as well as their diagnostic and therapeutic value of metabolic cardiometabolic diseases.
We welcome submissions of Original Research, Review and Mini-review articles on the following subtopics, but not limited to:
- Role of metabolic organ-secreted factors (hepatokines, adipokines, myokines, etc.) as biomarkers and targets for diagnosis of cardiovascular and metabolic diseases
- Receptors and corresponding signaling pathways responsible for the regulatory role of metabolic organ-secreted factors in cardiometabolic system
- Molecular mechanism of abnormal expression and secretion of metabolic organ-secreted factors in cardiovascular diseases
- Association between metabolic organ-secreted factors and pathological changes in cardiometabolic diseases, such as cardiac hypertrophy and vascular remodeling
- Role of metabolic organ-secreted factors in the treatment of cardiovascular diseases and molecular mechanism of the metabolic therapies on cardiovascular disease
- Crosstalk between local adipose tissue and cardiovascular cells
